Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Alexion Pharmaceuticals fell $1.86 (-1.4%) to $129.86 on average volume. Throughout the day, 1,011,284 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,054,300 shares. The stock ranged in price between $127.70-$132.00 after having opened the day at $131.66 as compared to the previous trading day's close of $131.72. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 21.6%, Prana Biotechnology ( PRAN), down 10.3%, Cardium Therapeutics ( CXM), down 9.3% and Sarepta Therapeutics ( SRPT), down 8.2%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $26.2 billion and is part of the health care sector. The company has a P/E ratio of 75.4, above the S&P 500 P/E ratio of 17.7. Shares are up 0.4% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Oxygen Biotherapeutics ( OXBT), up 15.6%, Peregrine Pharmaceuticals ( PPHM), up 14.5%, Cell Therapeutics ( CTIC), up 12.7% and Exelixis ( EXEL), up 11.1% , were all gainers within the drugs industry with Teva Pharmaceutical Industries ( TEVA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk